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ECONOMIC ASSESSMENT OF A PROPHYLACTIC 
TREATMENT OF RECURRENCE OF ISCHEMIC 
ACCIDENTS BY LYSINE ACETYLSALICYLATE
Marissal JP, Selke B, Lebrun T
CRESGE, Lille, France
Despite its low cost and its proven efficacy in prevention
of recurrence of ischemic events, acetylsalicylic acid is a
strategy not used in France as frequently as it should be.
OBJECTIVE: In order to convince practitioners and pub-
lic authorities, we provide a cost-effectiveness analysis
(CEA) of lysine acetylsalicylate (LA) 300 mg as compared
to “do nothing.” 
METHODS: We used Garber and Phelps’s specification
of CEA. Efficacy data were derived from the Antiplatelet
Trialists’ Collaboration meta-analysis. We used French
data sources to estimate the cost of the prophylactic treat-
ment, the cost of treatment-related side effects, and the
cost of nonfatal events to be prevented (ischemic stroke,
myocardial infarction). The perspective taken into ac-
count for this CEA is that of the French Social Security
system.
RESULTS: The results presented in the above table pro-
vide economic evidence of the interest of lysine acetylsali-
cylate in preventing ischemic accidents since the benefits
produced by the prophylactic treatment almost exceed
the costs induced by this strategy.
CONCLUSION: As a consequence, such negative net
costs induce savings for the Social Security system. There-
fore, the prescription of acetylsalicylic acid and, in partic-
ular, lysine acetylsalicylate is medically effective and eco-
nomically efficient.
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OUTCOME OF ACUTE MYOCARDIAL 
INFARCTION PATIENTS WITH MAXIMAL 
INDIVIDUAL THERAPY (MITRA-STUDY)
Dommke C, Schiele R, Fischer F, Wienbergen H,
Voigtländer T, Glunz HG, Berg G, Gieseler U,
Lauterbach KW, Senges J
Herzzentrum Ludwigshafen; Universität Cologne, for the 
MITRA Study Group, Cologne, Germany
Drugs improving prognosis in acute myocardial infarc-
tion (AMI) are underused in clinical practice, despite es-
tablished therapy from randomized trials.
METHODS:  MITRA (Maximal Individual TheRapy in
Acute myocardial infarction) is a AMI registry of 54 hos-
pitals in southwest Germany. The aim is a more frequent
use of therapies improving prognosis. In the MITRA-1
study (6/94 to 1/97) the use of thrombolysis or PTCA, as-
pirin, beta blocker, or ACE-inhibitor was increased. The
ongoing MITRA-2 study (6/98 to 6/99) is aimed at im-
proving the use of CSE inhibitors to lower cholesterol af-
ter AMI, and includes a cost-utility analysis.
RESULTS: The use of all four therapy forms increased
during the study, especially with beta blocker and ACE
inhibitor. This was associated with a significant decrease
in hospital mortality (	20%).
CONCLUSION: In clinical practice, many AMI patients
do not adequately receive prognostic therapy. In the
MITRA-1 study, the use of prognostic therapy was mark-
edly reduced, as was the outcome. In the ongoing
MITRA-2 study, the additional effect of an increased use
of cholesterol reduction (CSE inhibitor) is being evalu-
ated, together with a cost-utility analysis.
ECONOMIC AND OUTCOMES STUDY RESULTS 
FOR MENTAL HEALTH
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ROAD TRAFFIC ACCIDENTS ARE ASSOCIATED 
WITH BENZODIAZEPINE USE
Barbone F2, McMahon AD1, Davey P1, Morris AD,
McDevitt DG, MacDonald TM1
1Medicines Monitoring Unit (MEMO), University of Dundee, 
Ninewells Hospital & Medical School, Dundee, Scotland,
2Chair of Hygiene and Epidemiology, DPMSC, University of 
Udine, Italy
BACKGROUND: Psychomotor studies suggest that psy-
choactive drugs impair driving skills. We have examined
the association between the use of psychoactive drugs
and road traffic accidents (RTA).
METHODS: We carried out a case-crossover study of
drivers 18 years, resident in Tayside, Scotland, and who
experienced a first road traffic accident recorded by Tay-
side Police between 1 August 1992 and 30 June 1994.
Each driver had used one of the following drugs: tricyclic
antidepressant (TCA), selective serotonin reuptake inhibi-
tor (SSRI), benzodiazepines, or other psychotropics, be-
Cost-effectiveness ratios (1996 US$)
Endpoint
Qualifying event MI Ischemic stroke
Unstable angina 	5,703 190,711*
Prior MI 	15 	37
Prior ischemic stroke 	610 	176
Stable angina 4,375 15,749*
*Insignificant difference in efficacy between LA and placebo.
MITRA-1
Pilot
phase
Study
phase 1
Study
phase 2 P
6 mo 1 yr 1 yr
n  6068 1298 2678 2062
Lysis and/or PTCA 55% 58% 60% 0.003
Aspirin 88% 94% 96% 0.001
Beta blocker 33% 55% 62% 0.001
ACE inhibitor 16% 58% 63% 0.001
Hospital mortality 16.3% 16.1% 13.1% 0.005
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tween 1 August 1992 and the date of RTA. For each
driver, the probability of having the RTA while exposed to
a drug was compared with the probability while unex-
posed.
RESULTS: Of 19,386 drivers with a first RTA during the
study period, 1,731 were users of any study drug. On the
days of the accidents, 189 subjects were taking TCAs, 84
were taking selective SSRI, 235 were taking benzodiaz-
epines, and 47 were taking other psychoactive drugs. The
treatment-group exposure relative risks were 0.93 (95%
confidence interval [CI] 0.72–1.21) for TCAs, 0.85
(0.55–1.33) for SSRIs, 1.62 (1.24–2.12) for benzodiaz-
epines, and 0.88 (0.62–1.225) for other psychotropics.
The benzodiazepine risk decreased with increasing driver
age and increased in subjects with positive breath tests for
alcohol. A dose-response relationship was evident with
benzodiazepines, the relative risk increasing with dose.
CONCLUSION: Users of benzodiazepines were at in-
creased risks of experiencing a road traffic accident; how-
ever, users of TCAs and SSRIs were not. Users of benzo-
diazepines should not drive.
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NEW BENZODIAZEPINE USE IS ASSOCIATED 
WITH AN AGE-RELATED RISK OF 
HOSPITALIZATION WITH FRACTURE
AND OTHER TRAUMA: A POPULATION-
BASED STUDY
Steinke D1, Davey P1, Elliott L2, Dowell J3, Morris AD1, 
MacDonald TM1
1Medicines Monitoring Unit (MEMO), University of Dundee, 
Ninewells Hospital & Medical School, Dundee, Scotland; 
2Tayside School of Nursing & Midwifery; 3Tayside Centre for 
General Practice, Ninewells Hospital, Dundee, Scotland
OBJECTIVE: There are limited data linking benzodiaz-
epine prescribing to road traffic accidents (RTA) and hip
fractures but “epidemiological evidence for increased
risks of several kinds of accidents with benzodiazepine
use remains inconclusive.”
METHODS: We used a case control study. Between June
1993 and October 1995, 4019 people were admitted
with fractures and 3186 people were admitted with
trauma other than fracture from a fixed Tayside popula-
tion of 319,465. Of the population as a whole, 19,304
people were dispensed benzodiazepines between June
1993 and October 1995 but had not been exposed in the
previous 6 months.
RESULTS: Benzodiazepine users had an increased risk of
admission for fractures (odds ratio [OR] 1.9; 95% CI
1.7–2.1) and other trauma (OR 1.6; CI 1.4–1.8). The risk
of fracture was markedly age-related. The numbers needed
to treat (NNT) for one associated admission with frac-
ture was 95 (CI 79–120) for the whole population, but
the NNT fell from 199 (CI 111–918) at age 30–39 to 9
(CI 6–17) at age 90–99. The risk of other trauma was
also age-related but showed a bimodal distribution. The
NNT for one admission with other trauma were 163 (CI
126–234) for the whole population. At age 20–29 the
NNT was 72 (CI 47–154), rising to 376 at age 40–49 and
falling again to 61 (CI 38–167) at age 80–89.
CONCLUSION: These results challenge the widely held
belief that benzodiazepine drugs are safe with few serious
side effects.
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ASSESSING THE SASKATCHEWAN DATABASE 
FOR OUTCOMES STUDIES OF DEPRESSION AND 
ITS TREATMENT
West S, Richter A, Nennstiel M, Mauskopf JA
Research Triangle Institute, Research Triangle Park, NC, US
OBJECTIVE: Because antidepressants are prescribed for
numerous conditions, users of administrative databases
for conducting research on depression must be cautious.
We examined the Saskatchewan Health databases, con-
taining three-digit ICD-9 codes, concurrent medications,
prescriber information, comorbidities, and fee-for-service
codes, to determine their suitability for conducting depres-
sion research. 
METHODS: We identified a cohort of individuals who
began a “new” period of antidepressant use (no use 180
days prior) with at least one additional dispensation of
the antidepressant. A stratified random sample of 600 in-
dividuals was chosen for medical record abstraction. The
medical record abstraction classification of depression
was the gold standard against which our definitions of
depression were judged. We developed a primary defini-
tion of depression based on ICD-9 codes and tried to fur-
ther refine it with various algorithms. Since so few pa-
tients were false-positive and/or false-negative in the
primary classification, it was not feasible to split the data
and use pattern recognition techniques. Instead, we devel-
oped medically probable scenarios using the explanatory
variables and evaluated them for their sensitivity, speci-
ficity, and predictive values.
RESULTS: Defining depression using the ICD-9 codes
296 (affective disorders), 309 (adjustment reaction), and
311 (depressive disorders) had a sensitivity of 71%, a
specificity of 85%, a positive predictive value (PV
) of
86%, and a negative predictive value (PV	) of 70%. Us-
ing other definitions gave different results: limiting the
number of false-negatives raised the sensitivity to 84%
and the PV	 to 77%; limiting false-positives raised the
specificity 90% and PV
 to 86%. The false-negatives
had very similar characteristics to the true-positives.
CONCLUSION: The ICD-9 definition will permit future
studies of depression to be conducted using the Saskatch-
ewan Health databases.
